Abstract
Developing specific medications to treat (+)-methamphetamine (METH) addiction is a difficult challenge because METH has multiple sites of action that are intertwined with normal neurological function. As a result, no small molecule medication for the treatment of METH addiction has made it through the FDA clinical trials process. With the invention of a new generation of proteinbased therapies, it is now possible to consider treating drug addiction by an entirely different approach. This new approach is based on the discovery of very high affinity anti-METH monoclonal antibodies (mAbs), which are non-addictive and antagonize METH effects from the blood stream without entering the brain. Due to a very long biological half-life, anti-METH mAbs would only need to be administered once every 2-4 weeks, aiding in patient compliance. As a relapse prevention medication, anti-METH mAbs could reduce or prevent the rewarding effects of a relapse to METH use and thereby improve a patient's probability of remaining in therapy and recovering from their addiction. In this review, we discuss the discovery process of anti-METH mAbs, with a focus on the preclinical development leading to high affinity anti-METH mAb antagonists.
Keywords: Addiction, Amphetamines, monoclonal antibodies, pharmacokinetics, rat, vaccines, METH, cognitive behavioral therapy, psychosis, MAB6H4, PCKN
CNS & Neurological Disorders - Drug Targets
Title: Monoclonal Antibodies as Pharmacokinetic Antagonists for the Treatment of (+)-Methamphetamine Addiction
Volume: 10 Issue: 8
Author(s): S. Michael Owens, William T. Atchley, Michael D. Hambuchen, Eric C. Peterson and W. Brooks Gentry
Affiliation:
Keywords: Addiction, Amphetamines, monoclonal antibodies, pharmacokinetics, rat, vaccines, METH, cognitive behavioral therapy, psychosis, MAB6H4, PCKN
Abstract: Developing specific medications to treat (+)-methamphetamine (METH) addiction is a difficult challenge because METH has multiple sites of action that are intertwined with normal neurological function. As a result, no small molecule medication for the treatment of METH addiction has made it through the FDA clinical trials process. With the invention of a new generation of proteinbased therapies, it is now possible to consider treating drug addiction by an entirely different approach. This new approach is based on the discovery of very high affinity anti-METH monoclonal antibodies (mAbs), which are non-addictive and antagonize METH effects from the blood stream without entering the brain. Due to a very long biological half-life, anti-METH mAbs would only need to be administered once every 2-4 weeks, aiding in patient compliance. As a relapse prevention medication, anti-METH mAbs could reduce or prevent the rewarding effects of a relapse to METH use and thereby improve a patient's probability of remaining in therapy and recovering from their addiction. In this review, we discuss the discovery process of anti-METH mAbs, with a focus on the preclinical development leading to high affinity anti-METH mAb antagonists.
Export Options
About this article
Cite this article as:
Michael Owens S., T. Atchley William, D. Hambuchen Michael, C. Peterson Eric and Brooks Gentry W., Monoclonal Antibodies as Pharmacokinetic Antagonists for the Treatment of (+)-Methamphetamine Addiction, CNS & Neurological Disorders - Drug Targets 2011; 10 (8) . https://dx.doi.org/10.2174/187152711799219370
DOI https://dx.doi.org/10.2174/187152711799219370 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors as Promising Therapeutic Drugs for Diabetes: Status and Development
Current Medicinal Chemistry Medicinal Plants and Bioactive Compounds for Diabetes Management: Important Advances in Drug Discovery
Current Pharmaceutical Design Current Advancements in Aβ Luminescent Probes and Inhibitors of Aβ Aggregation
Current Alzheimer Research Privileged Structures as Leads in Medicinal Chemistry
Current Medicinal Chemistry Synthesis, Anti-inflammatory Activities and Mechanisms of 3,5- dihydroxycinnamic Acid Derivatives
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Novel Biomarkers Assessing the Calcium Deposition in Coronary Artery Disease
Current Medicinal Chemistry The Proteasome in Health and Disease
Current Pharmaceutical Design Role of Asymmetric Dimethylarginine (ADMA) in Diabetic Vascular Complications
Current Pharmaceutical Design 25OH-Vitamin D3 Levels in Obesity and Metabolic Syndrome—Unaltered in Young and not Correlated to Carotid IMT in All Ages
Current Pharmaceutical Design Ventricular and Vascular Stiffening in Aging and Hypertension
Current Hypertension Reviews Bioaccessibility of Bioactive Compounds and Prebiotic Properties of Fruit and Vegetable By-products - A Mini Review
Current Bioactive Compounds Eotaxins and CCR3 Receptor in Inflammatory and Allergic Skin Diseases: Therapeutical Implications
Current Drug Targets - Inflammation & Allergy Adeno-associated Viral Vectors for Correction of Inborn Errors of Metabolism: Progressing Towards Clinical Application
Current Pharmaceutical Design Neuropsychiatric Symptoms and Functional Status in Alzheimer’s Disease and Vascular Dementia Patients
Current Alzheimer Research Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry Pharmacological Treatment of Obesity, Food Intake, and Reversal of Metabolic Disorders
Current Nutrition & Food Science Recent Advances in Health Promoting Effect of Dietary Polyphenols
Current Nutrition & Food Science Irreversible Protein Kinase Inhibitors
Current Medicinal Chemistry Recent Advances in Inorganic Nanoparticle-Based Drug Delivery Systems
Mini-Reviews in Medicinal Chemistry Promising Activity of Mammalian Target of Rapamycin Inhibitors in Hematologic Malignancies Therapy
Current Signal Transduction Therapy